NeuroBo Pharmaceuticals Inc expected to post a loss of $1.12 a share - Earnings Preview
Brief: Neurobo Pharmaceuticals Doses First Patient In The Mad Part 2 Of Its Phase 1 Clinical Trial Evaluating DA-1726 For The Treatment Of Obesity
Brief: Neurobo Pharmaceuticals Announces Closing Of Up To $70 Million Concurrent Private Placement
Brief: Neurobo Pharmaceuticals Announces Up To $70 Mln Concurrent Private Placement And Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Neurobo Pharmaceuticals' Da-1726 Demonstrated Superiority In Weight Loss
U.S. STOCKS ON THE MOVE-Brady Corp, Moderna, crypto shares
U.S. STOCKS ON THE MOVE-Dorian, ChargePoint Holdings, Transcat
U.S. STOCKS ON THE MOVE-Edwards Lifesciences, Petco, Williams-Sonoma
NeuroBo rises on positive pre-clinical data for liver treatment
Brief: Neurobo Pharmaceuticals' Da-1241 In Combination With Semaglutide Improves Liver Fibrosis And Demonstrates Additive Hepatoprotective Effects In Pre-Clinical Mash Models Compared To Either Treatment, Alone
NeuroBo Pharma rises as dosing begins in early-stage obesity trial
Brief: NeuroBo Pharmaceuticals Doses First Patient In Its Phase 1 Clinical Trial Evaluating DA-1726 For The Treatment Of Obesity
Brief: Neurobo Pharmaceuticals Files For Mixed Shelf Offering Of Up To $150 Mln
Brief: NeuroBo Pharmaceuticals Completes Enrollment Of Part 1 Of Its Phase 2a Clinical Trial Evaluating DA-1241 For The Treatment Of MASH
NeuroBo Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
NeuroBo Pharmaceuticals Inc expected to post a loss of 78 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Vera Bradley, Rumble, Nvidia
U.S. STOCKS ON THE MOVE-Williams-Sonoma, US energy sector, gold miners
U.S. STOCKS ON THE MOVE-Nucor, ADM, SilverBow Resources